These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

134 related articles for article (PubMed ID: 10886213)

  • 1. Monitoring of minimal residual disease in patients with MLL-AF6-positive acute myeloid leukaemia by reverse transcriptase polymerase chain reaction.
    Mitterbauer G; Zimmer C; Pirc-Danoewinata H; Haas OA; Hojas S; Schwarzinger I; Greinix H; Jäger U; Lechner K; Mannhalter C
    Br J Haematol; 2000 Jun; 109(3):622-8. PubMed ID: 10886213
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Monitoring of minimal residual leukemia in patients with MLL-AF9 positive acute myeloid leukemia by RT-PCR.
    Mitterbauer G; Zimmer C; Fonatsch C; Haas O; Thalhammer-Scherrer R; Schwarzinger I; Kalhs P; Jaeger U; Lechner K; Mannhalter C
    Leukemia; 1999 Oct; 13(10):1519-24. PubMed ID: 10516752
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Incidence and characterization of MLL gene (11q23) rearrangements in acute myeloid leukemia M1 and M5.
    Poirel H; Rack K; Delabesse E; Radford-Weiss I; Troussard X; Debert C; Leboeuf D; Bastard C; Picard F; Veil-Buzyn A; Flandrin G; Bernard O; Macintyre E
    Blood; 1996 Mar; 87(6):2496-505. PubMed ID: 8630416
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Monitoring minimal residual disease in patients with MLL-AF6 fusion transcript-positive acute myeloid leukemia following allogeneic bone marrow transplantation.
    Takatsuki H; Yufu Y; Tachikawa Y; Uike N
    Int J Hematol; 2002 Apr; 75(3):298-301. PubMed ID: 11999359
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Acute myeloid leukemia with MLL rearrangements: clinicobiological features, prognostic impact and value of flow cytometry in the detection of residual leukemic cells.
    Muñoz L; Nomdedéu JF; Villamor N; Guardia R; Colomer D; Ribera JM; Torres JP; Berlanga JJ; Fernández C; Llorente A; Queipo de Llano MP; Sánchez JM; Brunet S; Sierra J;
    Leukemia; 2003 Jan; 17(1):76-82. PubMed ID: 12529663
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Clinical and experimental studies of childhood acute myeloid leukemia with 11q23/MLL rearrangements].
    He YX; Xue YQ; Wang HY; Shao XJ; Pan JL; Xu J; Yang NC; Ji ZH; Huang YP; Hu SY
    Zhonghua Yi Xue Yi Chuan Xue Za Zhi; 2012 Dec; 29(6):677-82. PubMed ID: 23225048
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A novel RT-qPCR assay for quantification of the MLL-MLLT3 fusion transcript in acute myeloid leukaemia.
    Abildgaard L; Ommen HB; Lausen B; Hasle H; Nyvold CG
    Eur J Haematol; 2013 Nov; 91(5):394-8. PubMed ID: 23772754
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Evaluation of minimal residual disease using reverse-transcription polymerase chain reaction in t(8;21) acute myeloid leukemia: a multicenter study of 51 patients.
    Morschhauser F; Cayuela JM; Martini S; Baruchel A; Rousselot P; Socié G; Berthou P; Jouet JP; Straetmans N; Sigaux F; Fenaux P; Preudhomme C
    J Clin Oncol; 2000 Feb; 18(4):788-94. PubMed ID: 10673520
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Analysis of the t(6;11)(q27;q23) in leukemia shows a consistent breakpoint in AF6 in three patients and in the ML-2 cell line.
    Tanabe S; Zeleznik-Le NJ; Kobayashi H; Vignon C; Espinosa R; LeBeau MM; Thirman MJ; Rowley JD
    Genes Chromosomes Cancer; 1996 Apr; 15(4):206-16. PubMed ID: 8703846
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prospective monitoring of minimal residual disease in acute myeloid leukemia with inversion(16) by CBFbeta/MYH11 RT-PCR: implications for a monitoring schedule and for treatment decisions.
    Laczika K; Mitterbauer G; Mitterbauer M; Knöbl P; Schwarzinger I; Greinix HT; Rabitsch W; Fonatsch C; Mannhalter C; Lechner K; Jaeger U
    Leuk Lymphoma; 2001; 42(5):923-31. PubMed ID: 11697647
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Clinical characteristics and prognosis of
    Zhang MX; Shi WZ; Liu JX; Wang CJ; Li Y; Wang W; Jiang B
    Beijing Da Xue Xue Bao Yi Xue Ban; 2021 Oct; 53(5):915-920. PubMed ID: 34650294
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Molecular disease eradication is a prerequisite for long-term remission in patients with t(8;21) positive acute myeloid leukemia: a single center study.
    Mitterbauer M; Mitterbauer-Hohendanner G; Sperr WR; Kalhs P; Greinix HT; Fonatsch C; Haas OA; Jäger U; Mannhalter C; Lechner K
    Leuk Lymphoma; 2004 May; 45(5):971-7. PubMed ID: 15291357
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The prognostic value of MLL-AF9 detection in patients with t(9;11)(p22;q23)-positive acute myeloid leukemia.
    Scholl C; Schlenk RF; Eiwen K; Döhner H; Fröhling S; Döhner K;
    Haematologica; 2005 Dec; 90(12):1626-34. PubMed ID: 16330435
    [TBL] [Abstract][Full Text] [Related]  

  • 14. RT-PCR and FISH analysis of acute myeloid leukemia with t(8;16)(p11;p13) and chimeric MOZ and CBP transcripts: breakpoint cluster region and clinical implications.
    Schmidt HH; Strehl S; Thaler D; Strunk D; Sill H; Linkesch W; Jäger U; Sperr W; Greinix HT; König M; Emberger W; Haas OA
    Leukemia; 2004 Jun; 18(6):1115-21. PubMed ID: 15085163
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Relevance of presenting white blood cell count and kinetics of molecular remission in the prognosis of acute myeloid leukemia with CBFbeta/MYH11 rearrangement.
    Martín G; Barragán E; Bolufer P; Chillón C; García-Sanz R; Gómez T; Brunet S; González M; Sanz MA
    Haematologica; 2000 Jul; 85(7):699-703. PubMed ID: 10897121
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Establishment and characterization of a human acute monocytic leukemic cell line, SHI-1, carrying t(6;11)(q27;23) and p53 gene alteration].
    Chen SN; Xue YQ; Zhang XG; Wu YF; Pan JL; Wang Y; Cen JN
    Zhonghua Xue Ye Xue Za Zhi; 2005 Feb; 26(2):94-9. PubMed ID: 15921626
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Fusion gene transcripts and Ig/TCR gene rearrangements are complementary but infrequent targets for PCR-based detection of minimal residual disease in acute myeloid leukemia.
    Boeckx N; Willemse MJ; Szczepanski T; van der Velden VH; Langerak AW; Vandekerckhove P; van Dongen JJ
    Leukemia; 2002 Mar; 16(3):368-75. PubMed ID: 11896540
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Acute promyelocytic leukemia: the study of t(15;17) translocation by fluorescent in situ hybridization, reverse transcriptase-polymerase chain reaction and cytogenetic techniques.
    Chauffaille ML; Figueiredo MS; Beltrani R; Antunes SV; Yamamoto M; Kerbauy J
    Braz J Med Biol Res; 2001 Jun; 34(6):735-43. PubMed ID: 11378661
    [TBL] [Abstract][Full Text] [Related]  

  • 19. MLL-AF6 fusion oncogene sequesters AF6 into the nucleus to trigger RAS activation in myeloid leukemia.
    Manara E; Baron E; Tregnago C; Aveic S; Bisio V; Bresolin S; Masetti R; Locatelli F; Basso G; Pigazzi M
    Blood; 2014 Jul; 124(2):263-72. PubMed ID: 24695851
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Molecular cytogenetic analysis of 10;11 rearrangements in acute myeloid leukemia.
    Van Limbergen H; Poppe B; Janssens A; De Bock R; De Paepe A; Noens L; Speleman F
    Leukemia; 2002 Mar; 16(3):344-51. PubMed ID: 11896537
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.